Meridian Bioscience Company Profile (NASDAQ:VIVO)

About Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience logoMeridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:VIVO
  • CUSIP: 58958410
  • Web:
  • Market Cap: $630.93 million
  • Outstanding Shares: 42,203,000
Average Prices:
  • 50 Day Moving Avg: $14.22
  • 200 Day Moving Avg: $14.35
  • 52 Week Range: $10.75 - $18.90
  • Trailing P/E Ratio: 29.80
  • Foreward P/E Ratio: 21.99
  • P/E Growth: 1.31
Sales & Book Value:
  • Annual Revenue: $198.07 million
  • Price / Sales: 3.19
  • Book Value: $3.97 per share
  • Price / Book: 3.77
  • Annual Dividend: $0.50
  • Dividend Yield: 3.5%
  • EBITDA: $52.8 million
  • Net Margins: 10.77%
  • Return on Equity: 16.93%
  • Return on Assets: 11.36%
  • Debt-to-Equity Ratio: 0.31%
  • Current Ratio: 6.47%
  • Quick Ratio: 4.42%
  • Average Volume: 201,783 shs.
  • Beta: 0.84
  • Short Ratio: 15.83

Frequently Asked Questions for Meridian Bioscience (NASDAQ:VIVO)

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience announced a quarterly dividend on Thursday, July 27th. Stockholders of record on Monday, August 7th will be paid a dividend of $0.125 per share on Thursday, August 17th. This represents a $0.50 annualized dividend and a dividend yield of 3.34%. The ex-dividend date is Thursday, August 3rd. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience Inc. (NASDAQ:VIVO) released its earnings results on Thursday, July, 27th. The company reported $0.16 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.16. The company had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The company's revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.21 EPS. View Meridian Bioscience's Earnings History.

When will Meridian Bioscience make its next earnings announcement?

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Meridian Bioscience.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $0.64-0.69 for the period, compared to the Thomson Reuters consensus estimate of $0.68. The company issued revenue guidance of $193-199 million, compared to the consensus revenue estimate of $197.58 million.

Where is Meridian Bioscience's stock going? Where will Meridian Bioscience's stock price be in 2017?

4 brokers have issued twelve-month target prices for Meridian Bioscience's shares. Their predictions range from $9.00 to $19.00. On average, they anticipate Meridian Bioscience's stock price to reach $14.00 in the next year. View Analyst Ratings for Meridian Bioscience.

Who are some of Meridian Bioscience's key competitors?

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the folowing people:

  • John A. Kraeutler, Chairman of the Board, President, Chief Executive Officer
  • Lawrence J. Baldini, Executive Vice President and President, Global Operations
  • Richard L. Eberly, Executive Vice President, President, Chief Commercial Officer
  • Melissa A. Lueke, Chief Financial Officer, Executive Vice President, Secretary
  • Marco G. Calzavara, President and Managing Director of Meridian Bioscience Europe
  • Vecheslav A. Elagin Ph.D., Executive Vice President - Research and Development
  • Susan D. Rolih, Executive Vice President - Regulatory & Quality Systems
  • David C. Phillips, Lead Independent Director
  • James M. Anderson, Independent Director
  • Dwight E. Ellingwood, Independent Director

Who owns Meridian Bioscience stock?

Meridian Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Eqis Capital Management Inc. (0.03%). Company insiders that own Meridian Bioscience stock include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.

Who bought Meridian Bioscience stock? Who is buying Meridian Bioscience stock?

Meridian Bioscience's stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have bought Meridian Bioscience stock in the last two years include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.

How do I buy Meridian Bioscience stock?

Shares of Meridian Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of Meridian Bioscience stock can currently be purchased for approximately $14.95.

MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)
Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Meridian Bioscience (NASDAQ:VIVO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings
Consensus Rating:Hold (Score: 1.75)
Consensus Price Target: $14.00 (6.35% downside)
Consensus Price Target History for Meridian Bioscience (NASDAQ:VIVO)
Price Target History for Meridian Bioscience (NASDAQ:VIVO)
Analysts' Ratings History for Meridian Bioscience (NASDAQ:VIVO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Canaccord GenuityReiterated RatingHold$14.00N/AView Rating Details
3/28/2017CL KingInitiated CoverageNeutral -> NeutralHighView Rating Details
1/31/2017Craig HallumDowngradeBuy -> HoldN/AView Rating Details
1/25/2017Piper Jaffray CompaniesSet Price TargetSell$9.00N/AView Rating Details
7/29/2016Hilliard LyonsDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Robert W. BairdReiterated RatingHold$20.00N/AView Rating Details
1/27/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Meridian Bioscience (NASDAQ:VIVO)
Earnings by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Earnings History by Quarter for Meridian Bioscience (NASDAQ VIVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017$0.15N/AView Earnings Details
7/27/2017Q3 2017$0.16$0.16$49.13 million$50.14 millionViewN/AView Earnings Details
4/28/2017Q2 2017$0.19$0.22$51.16 million$54.13 millionViewN/AView Earnings Details
1/25/2017Q1 2017$0.20$0.15$51.15 million$46.80 millionViewN/AView Earnings Details
11/10/2016Q4 2016$0.14$0.14$47.17 million$47.00 millionViewN/AView Earnings Details
7/28/2016Q3$0.22$0.21$52.85 million$50.70 millionViewN/AView Earnings Details
4/28/2016Q2$0.24$0.24$52.10 million$51.30 millionViewN/AView Earnings Details
1/27/2016Q1$0.21$0.21$48.60 million$47.20 millionViewN/AView Earnings Details
11/5/2015Q4$0.21$0.20$45.70 million$47.10 millionViewN/AView Earnings Details
7/23/2015Q3$0.22$0.22$48.60 million$48.20 millionViewN/AView Earnings Details
4/23/2015Q115$0.24$0.24$50.50 million$51.55 millionViewN/AView Earnings Details
1/22/2015Q414$0.19$0.19$46.20 million$48.00 millionViewN/AView Earnings Details
11/6/2014Q4$0.22$0.20$48.94 million$46.70 millionViewN/AView Earnings Details
7/24/2014Q3$0.22$0.21$47.96 million$47.20 millionViewN/AView Earnings Details
4/24/2014Q214$0.27$0.24$52.18 million$50.13 millionViewN/AView Earnings Details
1/22/2014Q114$0.18$0.18$47.59 million$44.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.23$0.22$49.24 million$48.96 millionViewN/AView Earnings Details
7/25/2013Q3 2013$0.21$0.24$47.00 million$47.10 millionViewN/AView Earnings Details
4/25/2013Q2 2013$0.24$0.24$49.66 million$47.26 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.19$0.20$44.34 million$45.40 millionViewN/AView Earnings Details
11/8/2012Q412$0.19$0.21$43.22 million$43.70 millionViewN/AView Earnings Details
7/26/2012$0.22$0.21ViewN/AView Earnings Details
4/26/2012$0.21$0.23ViewN/AView Earnings Details
1/25/2012$0.19$0.17ViewN/AView Earnings Details
11/10/2011$0.19$0.18ViewN/AView Earnings Details
7/21/2011$0.21$0.17ViewN/AView Earnings Details
4/21/2011$0.20$0.20ViewN/AView Earnings Details
1/20/2011$0.19$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Meridian Bioscience (NASDAQ:VIVO)
2017 EPS Consensus Estimate: $0.81
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.17$0.17$0.17
Q2 20171$0.22$0.22$0.22
Q3 20171$0.22$0.22$0.22
Q4 20171$0.20$0.20$0.20
(Data provided by Zacks Investment Research)


Current Dividend Information for Meridian Bioscience (NASDAQ:VIVO)
Most Recent Dividend:8/17/2017
Annual Dividend:$0.50
Dividend Yield:3.34%
Payout Ratio:98.04% (Trailing 12 Months of Earnings)
74.63% (Based on This Year's Estimates)
73.53% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Dividend History by Quarter for Meridian Bioscience (NASDAQ VIVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Meridian Bioscience (NASDAQ:VIVO)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 87.29%
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017John A KraeutlerChairmanBuy7,000$13.67$95,690.00View SEC Filing  
2/2/2017Melissa LuekeCFOBuy4,000$12.59$50,360.00View SEC Filing  
1/26/2017Lawrence BaldiniEVPBuy4,000$12.70$50,800.00View SEC Filing  
12/2/2016Vecheslav A ElaginEVPSell7,883$17.30$136,375.90View SEC Filing  
11/30/2016Dwight E EllingwoodDirectorBuy1,020$17.12$17,462.40View SEC Filing  
11/16/2016Richard EberlyEVPSell4,926$17.00$83,742.00View SEC Filing  
11/4/2016John A KraeutlerChairmanBuy5,000$16.13$80,650.00View SEC Filing  
11/3/2016Lawrence BaldiniEVPBuy4,900$16.00$78,400.00View SEC Filing  
8/11/2016John McilwraithDirectorBuy1,000$19.57$19,570.00View SEC Filing  
4/29/2016Catherine SazdanoffDirectorBuy7,700$19.20$147,840.00View SEC Filing  
12/9/2015Vecheslav A ElaginEVPSell7,500$19.75$148,125.00View SEC Filing  
12/1/2015Richard EberlyEVPSell4,934$19.61$96,755.74View SEC Filing  
3/2/2015Marviette D JohnsonVPSell1,917$19.91$38,167.47View SEC Filing  
1/23/2015Dwight E EllingwoodDirectorBuy1,980$17.74$35,125.20View SEC Filing  
12/1/2014Susan RolihEVPSell11,219$16.46$184,664.74View SEC Filing  
11/21/2014Dwight E EllingwoodDirectorBuy1,000$16.08$16,080.00View SEC Filing  
11/18/2014John A KraeutlerCEOSell10,500$16.20$170,100.00View SEC Filing  
11/18/2014Melissa LuekeCFOSell6,713$16.20$108,750.60View SEC Filing  
11/11/2014David PhillipsDirectorBuy10,000$16.89$168,900.00View SEC Filing  
6/13/2014Robert J ReadyDirectorSell2,700$20.03$54,081.00View SEC Filing  
12/5/2013Vecheslav ElaginEVPSell4,141$23.74$98,307.34View SEC Filing  
11/22/2013Susan RolihEVPSell9,086$24.18$219,699.48View SEC Filing  
11/21/2013Richard EberlyEVPSell4,926$24.50$120,687.00View SEC Filing  
11/19/2013Lawrence BaldiniVPSell4,926$24.26$119,504.76View SEC Filing  
11/11/2013John KraeutlerCEOSell5,250$25.27$132,667.50View SEC Filing  
7/26/2013Lawrence BaldiniVPSell32,000$24.14$772,480.00View SEC Filing  
5/1/2013John A KraeutlerCEOBuy5,000$19.63$98,150.00View SEC Filing  
12/3/2012Lawrence BaldiniVPSell32,500$20.00$650,000.00View SEC Filing  
11/13/2012Robert J ReadyDirectorSell1,800$19.46$35,028.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Meridian Bioscience (NASDAQ:VIVO)
Latest Headlines for Meridian Bioscience (NASDAQ:VIVO)
DateHeadline logoMeridian Bioscience, Inc. Expects to Report Fiscal 2018 Revenue and Earnings Guidance on Thursday, October 19, 2017 - October 17 at 8:50 AM logoOne of Cincinnati’s largest public companies names new CEO - October 16 at 7:42 AM logoMeridian Bioscience's (VIVO) Hold Rating Reaffirmed at Canaccord Genuity - October 14 at 5:16 PM logoETFs with exposure to Meridian Bioscience, Inc. : October 11, 2017 - October 11 at 4:49 PM logoZacks: Brokerages Expect Meridian Bioscience Inc. (VIVO) Will Announce Quarterly Sales of $47.70 Million - October 11 at 11:06 AM logoMeridian Bioscience, Inc. Appoints Jack Kenny as Chief Executive Officer - October 11 at 9:17 AM logoZacks: Analysts Anticipate Meridian Bioscience Inc. (VIVO) Will Announce Earnings of $0.14 Per Share - October 9 at 10:12 AM logoMeridian Bioscience Inc. (VIVO) Rating Increased to Hold at Zacks Investment Research - October 5 at 9:08 AM logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : September 25, 2017 - October 3 at 2:33 PM logoMeridian Bioscience Inc. (VIVO) Receives Consensus Rating of "Hold" from Brokerages - September 30 at 4:50 AM logoMeridian Bioscience (VIVO) vs. The Competition Financial Comparison - September 24 at 6:34 AM logo$47.70 Million in Sales Expected for Meridian Bioscience Inc. (VIVO) This Quarter - September 22 at 1:30 AM logoComparing Meridian Bioscience (VIVO) and CryoLife (CRY) - September 20 at 2:22 PM logoMeridian Contributes to Upcoming “LEADCON 2017” – Third Annual International Conference on the Prevention of Lead and Heavy Metal Toxicity in Hyderabad, India - September 19 at 9:22 AM logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : September 14, 2017 - September 15 at 11:01 AM logoMeridian Bioscience (VIVO) Launches TRU Block ULTRA - September 7 at 10:54 AM logoCytori Therapeutics (CYTX) & Meridian Bioscience (VIVO) Financial Analysis - September 6 at 8:26 PM logoMeridian Launches TRU Block® ULTRA – A Powerful Immunoassay Interference Blocker - September 6 at 9:53 AM logoMeridian Bioscience Inc. (VIVO) Given Consensus Recommendation of "Hold" by Analysts - September 5 at 4:32 AM logo Analysts Anticipate Meridian Bioscience Inc. (VIVO) Will Post Quarterly Sales of $47.70 Million - September 4 at 11:40 AM logo$0.14 EPS Expected for Meridian Bioscience Inc. (VIVO) This Quarter - September 2 at 4:20 AM logoETFs with exposure to Meridian Bioscience, Inc. : August 28, 2017 - August 29 at 9:26 AM logoInsider Buying: Meridian Bioscience Inc. (VIVO) Chairman Acquires 7,000 Shares of Stock - August 25 at 1:28 PM logoMeridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q3, 2017 By the Numbers : August 21, 2017 - August 23 at 1:32 PM logo Brokerages Anticipate Meridian Bioscience Inc. (VIVO) Will Announce Earnings of $0.15 Per Share - August 14 at 4:26 PM logoHead-To-Head Analysis: Meridian Bioscience (VIVO) and West Pharmaceutical Services (WST) - August 12 at 10:08 PM logoMeridian Bioscience Inc. (VIVO) Receives Consensus Recommendation of "Hold" from Analysts - August 11 at 10:56 AM logoMeridian (VIVO) Initiates illumigene CMV Trial, Shares Shine - August 10 at 9:27 AM logoMeridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test - August 10 at 9:27 AM logoMeridian Bioscience Elects John Rice to the Board of Directors - August 9 at 8:55 AM logoMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : August 8, 2017 - August 9 at 8:55 AM logoBioline Launches New JetSeq™ Clean Kit for Next-Generation Sequencing - August 3 at 8:36 AM logoMeridian Bioscience Inc. Plans Quarterly Dividend of $0.13 (NASDAQ:VIVO) - July 28 at 10:43 AM logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : July 27, 2017 - July 28 at 9:42 AM logoMeridian Bioscience meets 3Q profit forecasts - July 28 at 9:42 AM logoMeridian Bioscience Inc. (NASDAQ:VIVO) Announces Quarterly Earnings Results - July 27 at 2:17 PM logoMeridian Bioscience Inc. (NASDAQ:VIVO) Releases FY17 Earnings Guidance - July 27 at 10:07 AM logoMeridian Bioscience Q3 Profit Down 97%, Reiterates FY17 Outlook - Quick Facts - July 27 at 9:10 AM logoThe Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Meridian Bioscience, Inc. - July 27 at 9:10 AM logoMeridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results, Including Non-Cash Goodwill Impairment Charge,Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance Excluding the Effect of Goodwill Impairment Charge - July 27 at 9:10 AM logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Meridian Bioscience, Inc. - VIVO - July 26 at 9:48 AM logoMeridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China - July 21 at 8:26 AM logoMeridian Bioscience Inc. (VIVO) Given Consensus Rating of "Hold" by Analysts - July 17 at 11:05 AM logoFDA raises fresh concerns over Meridian's lead testing device - July 14 at 9:45 AM logoMeridian Bioscience Comments on Recent FDA Press Statement - July 14 at 9:45 AM logoFDA raises concerns about Meridian's plant that makes lead tests - July 14 at 9:45 AM logoVIVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Concerning Possible Securities Violations by Meridian Bioscience, Inc. - July 14 at 9:45 AM logoMERIDIAN BIOSCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Meridian Bioscience, Inc. To Contact The Firm - July 14 at 9:45 AM logoHead to Head Contrast: Hill-Rom Holdings (HRC) & Meridian Bioscience (VIVO) - July 12 at 7:47 AM logoMeridian Bioscience (VIVO) Publishes Clarifying Comments in Response to U.S. Senators, FDA & CDC Regarding FDA Safety Notification Request - July 1 at 8:50 AM



Meridian Bioscience (VIVO) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.